Drugs / QL2106
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07479576 | Nov 2025 → Apr 2026 overdue | — | Qilu Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07511647 | Jun 2026 → Dec 2027 expected | psoriasis | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QL2106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07479576 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT07479576 ↗ |